Document Detail


Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
MedLine Citation:
PMID:  23375187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine (PHEN) and topiramate extended-release (TPM ER). In the 56-week, randomized, double-blind, placebo-controlled, multicenter CONQUER trial, PHEN/TPM ER demonstrated significant weight loss compared with placebo in overweight or obese participants with ≥2 weight-related co-morbidities. Participants with body mass indexes of 27 to 45 kg/m(2) were randomized to placebo, PHEN 7.5 mg/TPM ER 46 mg, or PHEN 15 mg/TPM ER 92 mg; participants also received lifestyle modification counseling. Primary end points were percentage weight loss and the proportion of participants achieving ≥5% weight loss. Additional end points were changes in lipid variables in the dyslipidemia population and blood pressure in the hypertensive population, stratified by treatment and magnitude of weight loss. PHEN/TPM ER produced significantly greater dose-related mean percentage weight loss compared with placebo in the subgroups of participants with dyslipidemia and those with hypertension. Regardless of treatment group assignment, participants with dyslipidemia who lost ≥5% of their baseline weight experienced significantly greater reductions in triglycerides (-14.5% to -39.8%), and in non-high-density lipoprotein cholesterol (-9.4% to -14.8%) than those losing <5% of their weight (p <0.05). Similarly, participants with hypertension at baseline showed reduced systolic blood pressure by -7.5 to -11.8 mm Hg (p <0.001 vs those with <5% weight loss). In conclusion, the dose-related weight loss induced by PHEN/TPM ER treatment was accompanied by significant improvements in cardiovascular disease risk factors in participants who had dyslipidemia or hypertension at baseline, suggesting that facilitating weight loss by augmenting lifestyle changes with pharmacotherapies may decrease the risk for cardiovascular disease in obese and overweight patients with co-morbidities.
Authors:
Michael H Davidson; Serena Tonstad; Suzanne Oparil; Michael Schwiers; Wesley W Day; Charles H Bowden
Related Documents :
19820987 - Peripheral chemoreflex regulation of sympathetic vasomotor tone in apnea divers.
8252587 - Effect of hypoxia and reoxygenation on the isolated rabbit heart determined by monoclon...
23455767 - Torricelli and the ocean of air: the first measurement of barometric pressure.
647497 - Microangiography and vascular permeability of the subependymal matrix in the premature ...
11036577 - A virtual instrument (vi) for haemodynamic management in icu and during surgery.
8823147 - 1995 update of the working group reports on chronic renal failure and renovascular hype...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-29
Journal Detail:
Title:  The American journal of cardiology     Volume:  111     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-05     Completed Date:  2013-05-27     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1131-8     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Affiliation:
University of Chicago, Chicago, IL, USA. mdavidsonmd@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Obesity Agents / adverse effects*
Biological Markers / blood
Body Mass Index
Cardiovascular Diseases / prevention & control*
Comorbidity
Delayed-Action Preparations / administration & dosage
Female
Fructose / adverse effects,  analogs & derivatives*
Humans
Male
Middle Aged
Obesity / drug therapy*
Phentermine / adverse effects*
Risk
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Biological Markers; 0/Delayed-Action Preparations; 0H73WJJ391/topiramate; 122-09-8/Phentermine; 30237-26-4/Fructose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relation between leukocyte telomere length and incident coronary heart disease events (from the 1995...
Next Document:  Who are we and where are we going? Primary care academics in non-clinical posts.